MX2015010083A - Nanoparticulas biodegradables y clinicamente compatibles como portadores para administracion de farmacos. - Google Patents
Nanoparticulas biodegradables y clinicamente compatibles como portadores para administracion de farmacos.Info
- Publication number
- MX2015010083A MX2015010083A MX2015010083A MX2015010083A MX2015010083A MX 2015010083 A MX2015010083 A MX 2015010083A MX 2015010083 A MX2015010083 A MX 2015010083A MX 2015010083 A MX2015010083 A MX 2015010083A MX 2015010083 A MX2015010083 A MX 2015010083A
- Authority
- MX
- Mexico
- Prior art keywords
- drug delivery
- biodegradable
- clinically
- compatible
- delivery carriers
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title abstract 4
- 238000012377 drug delivery Methods 0.000 title abstract 2
- 239000000969 carrier Substances 0.000 title 1
- 108020004459 Small interfering RNA Proteins 0.000 abstract 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 abstract 1
- 229960002261 magnesium phosphate Drugs 0.000 abstract 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 abstract 1
- 239000004137 magnesium phosphate Substances 0.000 abstract 1
- 235000010994 magnesium phosphates Nutrition 0.000 abstract 1
- 159000000003 magnesium salts Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Ceramic Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361761012P | 2013-02-05 | 2013-02-05 | |
| PCT/US2014/014751 WO2014123935A1 (en) | 2013-02-05 | 2014-02-05 | Biodegradable and clinically-compatible nanop articles as drug delivery carriers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015010083A true MX2015010083A (es) | 2016-04-26 |
Family
ID=51300093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015010083A MX2015010083A (es) | 2013-02-05 | 2014-02-05 | Nanoparticulas biodegradables y clinicamente compatibles como portadores para administracion de farmacos. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11001840B2 (enExample) |
| EP (2) | EP3845248A1 (enExample) |
| JP (1) | JP6507102B2 (enExample) |
| KR (1) | KR20150132131A (enExample) |
| AU (2) | AU2014215421A1 (enExample) |
| CA (1) | CA2899155A1 (enExample) |
| ES (1) | ES2873600T3 (enExample) |
| IL (1) | IL240148A0 (enExample) |
| MX (1) | MX2015010083A (enExample) |
| RU (1) | RU2015137815A (enExample) |
| SG (2) | SG10201706968UA (enExample) |
| WO (1) | WO2014123935A1 (enExample) |
| ZA (1) | ZA201506530B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014123935A1 (en) | 2013-02-05 | 2014-08-14 | 1Globe Health Institute Llc | Biodegradable and clinically-compatible nanop articles as drug delivery carriers |
| WO2015013673A1 (en) | 2013-07-25 | 2015-01-29 | Aurasense Therapeutics, Llc | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
| US10434064B2 (en) | 2014-06-04 | 2019-10-08 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| EP3183007B1 (en) | 2014-08-19 | 2020-06-17 | Northwestern University | Protein/oligonucleotide core-shell nanoparticle therapeutics |
| CA2968531A1 (en) | 2014-11-21 | 2016-05-26 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| EP3247796A4 (en) * | 2015-01-14 | 2018-07-11 | Exicure, Inc. | Nucleic acid nanostructures with core motifs |
| KR102617833B1 (ko) | 2016-05-06 | 2023-12-27 | 엑시큐어 오퍼레이팅 컴퍼니 | 인터류킨 17 수용체 mRNA의 특이적 녹다운을 위한 안티센스 올리고뉴클레오티드 (ASO)를 제시하는 리포좀성 구형 핵산 (SNA) 구축물 |
| WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
| WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
| US10800817B2 (en) | 2016-12-19 | 2020-10-13 | Morehouse School Of Medicine | Compositions and methods for treating diseases by inhibiting exosome release |
| EP3568122B1 (en) * | 2017-01-10 | 2023-10-04 | Dukebox SP. Z O.O. | A method of manufacturing a suspension of nanoparticles of potassium salt or magnesium salt |
| US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| KR102120482B1 (ko) | 2018-10-05 | 2020-06-08 | 씨제이제일제당 (주) | 생분해성 고분자 나노입자를 포함하는 메모리 소자 및 이의 제조방법 |
| JP2022540665A (ja) * | 2019-07-12 | 2022-09-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 機能化されたナノ粒子および細菌感染症の治療におけるその使用 |
| WO2021067952A1 (en) * | 2019-10-04 | 2021-04-08 | The University Of Chicago | Targeted nanomedicine for treating vascular disorders |
| EP4100021A4 (en) * | 2020-02-03 | 2023-11-15 | Rutgers, the State University of New Jersey | MICRORNA-7 COMPOSITIONS FOR PROMOTING FUNCTIONAL RECOVERY AFTER SPINAL CORD INJURY AND METHODS OF USE THEREOF |
| US11998615B2 (en) | 2021-04-14 | 2024-06-04 | The Board Of Trustees Of The Leland Stanford Junior University | Functionalized nanoparticles and their use in treating bacterial infections |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5219577A (en) | 1990-06-22 | 1993-06-15 | The Regents Of The University Of California | Biologically active composition having a nanocrystalline core |
| TW406020B (en) * | 1993-09-29 | 2000-09-21 | Bristol Myers Squibb Co | Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent |
| US5879715A (en) * | 1997-09-02 | 1999-03-09 | Ceramem Corporation | Process and system for production of inorganic nanoparticles |
| DE19856432A1 (de) * | 1998-12-08 | 2000-06-15 | Basf Ag | Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen |
| DE19912502A1 (de) | 1999-03-19 | 2000-09-21 | Inst Neue Mat Gemein Gmbh | Nanoskalige Teilchen, Komplexe mit Polynukleotiden und deren Verwendung |
| AU2002214854A1 (en) | 2000-10-25 | 2002-05-06 | Inex Pharmaceuticals Corporation | Lipid formulations for target delivery |
| IN192520B (enExample) * | 2001-08-01 | 2004-04-24 | Univ Delhi | |
| SG190613A1 (en) | 2003-07-16 | 2013-06-28 | Protiva Biotherapeutics Inc | Lipid encapsulated interfering rna |
| ATE470433T1 (de) | 2004-02-13 | 2010-06-15 | Nod Pharmaceuticals Inc | Partikel mit kern aus calciumphosphat- nanopartikeln, biomolekül und gallensäure, herstellungsverfahren und therapeutische verwendung |
| US7611690B2 (en) | 2005-01-04 | 2009-11-03 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
| US20110081410A1 (en) | 2005-06-28 | 2011-04-07 | St. Marianna University, School Ofmedicine | Therapeutic agent for local inflammation |
| CN100435784C (zh) | 2005-07-25 | 2008-11-26 | 管晓虹 | 含有和包封中药成分的无机盐纳米粒子的制备方法 |
| WO2008045806A2 (en) * | 2006-10-06 | 2008-04-17 | Microislet, Inc. | Multilayered polyelectrolyte-based capsules for cell encapsulation and delivery of therapeutic compositions |
| MX2009011218A (es) | 2007-04-17 | 2010-02-11 | Baxter Int | Microparticulas de acido nucleico para administracion pulmonar. |
| US20110038939A1 (en) * | 2007-07-16 | 2011-02-17 | Northeastern University | Therapeutic stable nanoparticles |
| ES2873350T3 (es) * | 2007-08-27 | 2021-11-03 | 1Globe Health Inst Llc | Composiciones de ARN interferente asimétrico y usos de las mismas |
| EP2197454A4 (en) | 2007-09-25 | 2012-07-04 | Idexx Lab Inc | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF OLIGONUCLEOTIDES |
| JP4647706B2 (ja) | 2007-12-14 | 2011-03-09 | 江崎グリコ株式会社 | α−リポ酸ナノ粒子およびその調製方法 |
| US20110038941A1 (en) | 2007-12-27 | 2011-02-17 | The Ohio State University Research Foundation | Lipid Nanoparticle Compositions and Methods of Making and Using the Same |
| KR20110026424A (ko) | 2008-05-13 | 2011-03-15 | 유니버시티 오브 워싱톤 | 중합체 캐리어 |
| JP2012509904A (ja) | 2008-11-26 | 2012-04-26 | ユニバーシティ・オブ・カンザス | 核酸送達組成物および核酸送達法 |
| ES2381022T3 (es) | 2008-12-19 | 2012-05-22 | Biolitec Ag | Nanopartículas de fosfato de calcio como vehículo de colorantes para la terapia fotodinámica |
| US9937128B2 (en) * | 2009-08-03 | 2018-04-10 | The University Of North Carolina At Chapel Hill | Liposomes comprising a calcium phosphate-containing precipitate |
| JP2013504337A (ja) * | 2009-09-14 | 2013-02-07 | ナノハイブリッド カンパニー リミテッド | 標的特異的ｓｉＲＮＡ−層状無機水酸化物ナノハイブリッド、その製造方法、及びナノハイブリッドを含有する腫瘍治療用の医薬組成物 |
| JP5491119B2 (ja) * | 2009-10-02 | 2014-05-14 | 日東電工株式会社 | 薬物含有微粒子を含む医薬組成物およびその製造方法 |
| WO2011140024A2 (en) * | 2010-05-03 | 2011-11-10 | University Of Utah Research Foundation | Nanoparticles produced from recombinant polymers and methods of making and using the same |
| WO2013040295A2 (en) * | 2011-09-14 | 2013-03-21 | University Of South Florida | Divalent-metal coated nanoparticles for delivery of compositions into the central nervous system by nasal insufflation |
| CA2853689C (en) | 2011-11-04 | 2020-06-30 | Nitto Denko Corporation | Method of producing lipid nanoparticles for drug delivery |
| US20130243699A1 (en) * | 2011-12-07 | 2013-09-19 | Regents Of The University Of Minnesota | Biodegradable Magnetic Nanoparticles and Related Methods |
| ITRM20120480A1 (it) | 2012-10-09 | 2014-04-10 | Uni Degli Studi Camerino | Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione. |
| WO2014123935A1 (en) | 2013-02-05 | 2014-08-14 | 1Globe Health Institute Llc | Biodegradable and clinically-compatible nanop articles as drug delivery carriers |
-
2014
- 2014-02-05 WO PCT/US2014/014751 patent/WO2014123935A1/en not_active Ceased
- 2014-02-05 EP EP20204049.9A patent/EP3845248A1/en active Pending
- 2014-02-05 US US14/765,763 patent/US11001840B2/en active Active
- 2014-02-05 EP EP14748796.1A patent/EP2953646B1/en active Active
- 2014-02-05 CA CA2899155A patent/CA2899155A1/en not_active Abandoned
- 2014-02-05 ES ES14748796T patent/ES2873600T3/es active Active
- 2014-02-05 AU AU2014215421A patent/AU2014215421A1/en not_active Abandoned
- 2014-02-05 KR KR1020157024176A patent/KR20150132131A/ko not_active Withdrawn
- 2014-02-05 SG SG10201706968UA patent/SG10201706968UA/en unknown
- 2014-02-05 RU RU2015137815A patent/RU2015137815A/ru not_active Application Discontinuation
- 2014-02-05 SG SG11201506116XA patent/SG11201506116XA/en unknown
- 2014-02-05 MX MX2015010083A patent/MX2015010083A/es unknown
- 2014-02-05 JP JP2015556243A patent/JP6507102B2/ja active Active
-
2015
- 2015-07-26 IL IL240148A patent/IL240148A0/en unknown
- 2015-09-04 ZA ZA2015/06530A patent/ZA201506530B/en unknown
-
2018
- 2018-02-07 AU AU2018200903A patent/AU2018200903A1/en not_active Abandoned
-
2021
- 2021-04-06 US US17/223,647 patent/US20210230595A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP6507102B2 (ja) | 2019-04-24 |
| ES2873600T3 (es) | 2021-11-03 |
| IL240148A0 (en) | 2015-09-24 |
| ZA201506530B (en) | 2018-11-28 |
| US20160046936A1 (en) | 2016-02-18 |
| KR20150132131A (ko) | 2015-11-25 |
| SG11201506116XA (en) | 2015-09-29 |
| CA2899155A1 (en) | 2014-08-14 |
| EP2953646A4 (en) | 2017-02-15 |
| WO2014123935A9 (en) | 2014-10-23 |
| EP2953646B1 (en) | 2021-03-10 |
| AU2018200903A1 (en) | 2018-02-22 |
| WO2014123935A1 (en) | 2014-08-14 |
| RU2015137815A (ru) | 2017-03-13 |
| HK1217906A1 (en) | 2017-01-27 |
| US20210230595A1 (en) | 2021-07-29 |
| AU2014215421A1 (en) | 2015-08-13 |
| SG10201706968UA (en) | 2017-09-28 |
| EP2953646A1 (en) | 2015-12-16 |
| JP2016513090A (ja) | 2016-05-12 |
| US11001840B2 (en) | 2021-05-11 |
| EP3845248A1 (en) | 2021-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015010083A (es) | Nanoparticulas biodegradables y clinicamente compatibles como portadores para administracion de farmacos. | |
| MX350589B (es) | Copolimeros funcionales pla-peg, las nanoparticulas de los mismos, su preparacion y su uso para la administracion dirigida de farmacos e imagenologia. | |
| EA032943B1 (ru) | Способ получения терапевтических наночастиц (варианты) и терапевтическая наночастица (варианты) | |
| EP3065713A4 (en) | Nanoscale carriers for the delivery or co-delivery of chemotherapeutics, nucleic acids and photosensitizers | |
| MX2023008180A (es) | Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz. | |
| WO2014191359A9 (en) | Aptamers and use of the aptamers in the diagnosis and treatment of cancer | |
| MX2017002085A (es) | Tratamientos con nanopartículas núcleo-corteza de proteína/oligonucleótido. | |
| MX2021011906A (es) | Composiciones de liberacion retardada de linaclotida. | |
| IN2015KN00005A (enExample) | ||
| PH12015500900B1 (en) | A stabilized pemetrexed formulation | |
| WO2015058664A8 (zh) | 淫羊藿苷元在制备预防或治疗血细胞减少药物中的用途 | |
| EP2999461A4 (en) | Targeted delivery of drugs to the myometrium | |
| AU2014271207A1 (en) | Targeted delivery of drugs to the myometrium | |
| SMT202200275T1 (it) | Nanoparticelle quali veicoli di rilascio di principi attivi e metodi per la loro produzione | |
| WO2012040331A3 (en) | Multistage nanoparticles | |
| SG10201902499VA (en) | Therapeutic nanoparticles and related compositions, methods and systems | |
| MX371349B (es) | Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz. | |
| MX2016006927A (es) | Compuesto de la familia de la avermectina o de la familia de la milbemicina para el tratamiento y/o la prevencion de la dermatitis atopica. | |
| EP3079664A4 (en) | Regionally activated drug delivery nanoparticles | |
| IN2013MU02469A (enExample) | ||
| NZ711046A (en) | Nanoparticles containing a taxane and their use | |
| AU2012100284A4 (en) | Erectile Dysfunction Patch | |
| IN2013MU03801A (enExample) | ||
| IN2013MU02953A (enExample) | ||
| IN2013CH02437A (enExample) |